相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。An Institutional Guide for Formulary Decisions of Biosimilars
Sherin Ismail et al.
HOSPITAL PHARMACY (2023)
Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer
Rami Nassir et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2022)
Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
Yazed AlRuthia et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2021)
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Ioana Gherghescu et al.
PHARMACEUTICS (2021)
Incidence trends of breast cancer in Saudi Arabia: A joinpoint regression analysis (2004-2016)
Salman M. Albeshan et al.
JOURNAL OF KING SAUD UNIVERSITY SCIENCE (2021)
Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
Shruti Rastogi et al.
BIOLOGY-BASEL (2021)
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2021)
The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia
Ahmed Alghamdi et al.
HEALTHCARE (2021)
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2021)
Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
Karen MacDonald et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
Salvatore Bellinvia et al.
BIODRUGS (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
First GCC stakeholder meeting on approval process, interchange-ability/substitution and safety of biosimilars 2017 - Report
Gianluca Trifiro et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2018)
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz
Ali McBride et al.
FUTURE ONCOLOGY (2017)
The rise of biosimilars: How they got here and where they are going
Dhiren Patel et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Pere Gascon et al.
SUPPORTIVE CARE IN CANCER (2016)
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
M. Aapro et al.
ANNALS OF ONCOLOGY (2016)
Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study
Diana Sun et al.
CLINICAL THERAPEUTICS (2015)
Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries
Ivo Abraham et al.
FUTURE ONCOLOGY (2014)
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
Parvin F. Peddi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors
Ivo Abraham et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Clinical experience with ZarzioA® in Europe: what have we learned?
Pere Gascon et al.
SUPPORTIVE CARE IN CANCER (2013)
Biosimilars in 3D Definition, development and differentiation
Ivo Abraham et al.
BIOENGINEERED (2013)
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
Matti Aapro et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia
Matti Aapro et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Development of a new G-CSF product based on biosimilarity assessment
P. Gascon et al.
ANNALS OF ONCOLOGY (2010)
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
D Weycker et al.
ANNALS OF PHARMACOTHERAPY (2006)